USP14 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Alternative names
Deubiquitinating enzyme 14, UBP14_HUMAN, USP 14, Ubiquitin carboxyl-terminal hydrolase 14, Ubiquitin specific peptidase 14, Ubiquitin specific protease 14, Ubiquitin thiolesterase 14, Ubiquitin-specific-processing protease 14, tRNA guanine transglycosylase 60 kD subunit, tRNA-guanine transglycosylase
What's included?
Recommended products
USP14 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- USP14
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
USP14 also known as Ubiquitin Specific Peptidase 14 is a deubiquitinating enzyme that plays a mechanical role in the ubiquitin-proteasome system. This enzyme has a molecular mass around 56 kDa and is essential for proteasome-mediated degradation activities. It is broadly expressed across many tissues but shows significant presence in the nervous system. Often people refer to USP14 as TGT in the context of certain studies or databases.
- Biological function summary
USP14 functions in regulating protein turnover by removing ubiquitin from substrate proteins impacting their stability and degradation. USP14 is part of a larger protein complex associated with the proteasome specifically binding to the 19S regulatory particle. It is important in maintaining cellular protein homeostasis by editing ubiquitin chains on target proteins prior to degradation.
- Pathways
USP14 participates in ubiquitin-proteasome pathways and ER-associated degradation pathway. In these processes it works closely with other proteasome proteins such as Rpn11 which also removes ubiquitin from proteins. The regulation of these pathways by USP14 directly affects protein quality control in cells influencing processes like cell cycle and stress response.
- Associated diseases and disorders
USP14 has associations with neurodegenerative diseases such as Alzheimer's and Parkinson’s. It affects disease progression by modulating levels of proteins that aggregate in these conditions. Connections between USP14 and proteins such as tau and α-synuclein highlight its contribution to the pathological features seen in these disorders. Further research into USP14's role may help to uncover new therapeutic strategies for these diseases.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human USP14 (TGT) knockout HeLa cell lysate (ab257787)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: USP14 knockout HeLa cell lysate 20 μg
Lane 3: USP14 knockout HeLa cell lysate 20 μg
False colour image of Western blot: Anti-USP14/TGT antibody [EPR15943] - C-terminal staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-USP14/TGT antibody [EPR15943] - C-terminal ab192618 was shown to bind specifically to USP14/TGT. A band was observed at 63 kDa in wild-type HeLa cell lysates with no signal observed at this size in USP14 knockout cell line Human USP14 (TGT) knockout HeLa cell line ab266854 (knockout cell lysate ab257787). The band observed in the knockout lysate lane below 63 kDa is likely to represent a truncated form of USP14/TGT. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and USP14 knockout HeLa cell lysates were analysed.First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-USP14/TGT antibody [EPR15943] - C-terminal (Anti-USP14/TGT antibody [EPR15943] - C-terminal ab192618) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lanes 2 - 3: USP14 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 63 kDa
Sanger Sequencing - Human USP14 (TGT) knockout HeLa cell lysate (ab257787)
Homozygous: 1 bp insertion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com